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Summary
Drug-induced liver injury (DILI) is often caused by innate and adaptive host
immune responses. Characterization of inflammatory infiltrates in the liver
may improve understanding of the underlying pathogenesis of DILI. This
study aimed to enumerate and characterize leucocytes infiltrating liver tissue
from subjects with acute DILI (n = 32) versus non-DILI causes of acute liver
injury (n = 25). Immunostains for CD11b/CD4 (Kupffer and T helper cells),
CD3/CD20 (T and B cells) and CD8/CD56 [T cytotoxic and natural killer
(NK) cells] were evaluated in biopsies from subjects with acute DILI, either
immunoallergic (IAD) or autoimmune (AID) and idiopathic autoimmune
(AIH) and viral hepatitis (VH) and correlated with clinical and pathological
features. All biopsies showed numerous CD8+ T cells and macrophages. DILI
cases had significantly fewer B lymphocytes than AIH and VH and signifi-
cantly fewer NK cells than VH. Prominent plasma cells were unusual in IAD
(three of 10 cases), but were associated strongly with AIH (eight of nine) and
also observed in most with AID (six of nine). They were also found in five of
10 cases with VH. Liver biopsies from subjects with DILI were characterized
by low counts of mature B cells and NK cells in portal triads in contrast to
VH. NK cells were found only in cases of VH, whereas AIH and VH both
showed higher counts of B cells than DILI. Plasma cells were associated most
strongly with AIH and less so with AID, but were uncommon in IAD.
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Introduction
Acute liver failure (ALF) or fulminant hepatitis (FH) has a
mortality rate >70% in the absence of supportive manage-
ment or liver transplantation [1]. In the United States,
ALF/FH is due mainly to drug-induced liver injury (DILI),
viral hepatitis (VH) and idiopathic autoimmune hepatitis
AIH). Reliable biomarkers are available to aid in the
diagnosis of VH and AIH (e.g. serological testing for hepati-
tis A–E viral antigens, antibodies and nucleic acids [2], or
evidence of autoantibodies and hyperglobulinaemia [3,4],
respectively). Conversely, drug-induced liver injury (DILI)
is more difficult to establish and is often missed. Currently,
it is a diagnosis of exclusion and relies upon a history of
exposure to an agent that causes liver injury (drug, herbal
product or dietary supplement) and upon exclusion of
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other potential causes, such as viral, autoimmune or
ischaemic hepatitis or extrahepatic obstruction of the bile
ducts.
The normal liver contains resident immune cells that
differ in proportion from those in peripheral blood. These
include a large number of natural killer (NK) and Kupffer
cells. These specialized immune cells play essential roles in
both liver immune homeostasis and the immunopathology
of liver diseases. For example, NK cells participate with
CD8+ cytotoxic T cells in suppression of liver metastases
[5]. Dramatic increases of hepatic NK cells have been
described in hepatitis C virus (HCV)-infected livers, and
early release of type I–III interferons (IFNs) by NK cells
has been shown to be associated with effective clearance of
the virus in those individuals who clear the infection
spontaneously [6,7]. Kupffer cells produce large amounts
of tumour necrosis factor (TNF)-α in response to micro-
bial infection [8]. Activation of Kupffer cells, and
subsequent nitric oxide (NO) production, are major deter-
minants of peroxynitrite formation and, inter alia, severity
of acetaminophen liver toxicity [9]. While the liver is a site
where lymphocytes undergo apoptosis during the
clearance/resolution phase of peripheral immune response,
infiltrating activated B and T lymphocytes in diseased
livers have also been associated with hepatic histopathol-
ogy. For instance, the ratio between pro- and anti-
inflammatory CD4+ T helper lymphocytes in the liver can
alter the balance in favour of or against fibrosis in
Schistosoma mansoni-infected mice [10], and CCl4-induced
fibrosis is reduced in B cell-deficient mice [11].
To date, there have been few, if any, studies that have
carefully enumerated or characterized the leucocytes that
infiltrate the livers of patients with clinically impor-
tant DILI, compared to liver injury of other causes. In
this work we enumerated and characterized portal
mononuclear cell infiltrates of liver biopsies from subjects
with acute hepatitis of DILI (with autoimmune or
immunoallergic features) or non-DILI origins (idiopa-
thic autoimmune, viral), and correlated clinical and
histopathological features with particular profiles of liver-
infiltrating leucocytes. Hepatic immune profiles were also
established, in an exploratory fashion, for cases of acute
intrinsic-type DILI (e.g. triggered by acetaminophen) or
liver injury associated with the use of herbal remedies. We
have developed and optimized procedures for dual-
immunohistochemical (IHC) staining of mononuclear
cells of myeloid (macrophages/Kupffer cells) and lymphoid
(T, B and NK cells) origin infiltrating the liver. In hepatic
portal triads, macrophages (CD11b+) and T cells (CD3+)
were predominant in injured liver, regardless of the causa-
tive drug or clinicopathological phenotype, and were asso-
ciated with the degree of liver damage. T cytotoxic (CD8+)
cells represented more than 90% of total T cell infiltrates
in the liver. While liver tissue from DILI subjects had few
B cells (CD20+), they were numerous in idiopathic AIH
and acute VH. Ninety per cent of idiopathic AIH subjects
and 70% of autoimmune DILI cases (AID) had significant
portal hepatic plasma cells infiltrate. NK cells (CD56+)
were found only in liver biopsies obtained from subjects
with VH.
Material and methods
Subjects studied
Liver tissues from 57 subjects with acute hepatitis were
investigated in this study. Selection criteria for biopsy or
explanted liver to be included in the study were: (i) well-
characterized trigger of liver inflammation, (ii) complete
pathology report available, (iii) complete laboratory results
available (including blood count, hepatic/renal damage
markers), (iv) complete medical history available
(including medications and herbals taken) and (v) immune
features and causative drug(s) available for DILI patients.
Diagnosis of acute VH was based on compatible history,
physical examination, abdominal imaging studies and on
seropositivity for acute HBV, HCV or HEV infection.
Diagnosis of idiopathic AIH was based on compatible
clinical presentation, exclusion of DILI or VH as cause and
presence of circulating autoantibodies, as well as high
prevalence of hepatic plasma cells. Eleven AIH cases and
14 VH cases (seven due to HBV, six to HCV and one to
HEV) were included in the study (Table 1). Liver samples
were retrieved from tissue blocks stored at Carolinas
Healthcare System (CHS)’s Pathology Department of
Pathology or provided by the acute liver failure (ALF)
study group. They included 18 needle biopsies, six
explanted livers and one from autopsy (selected by H.L.B.,
W.A.A. and C.J. from CHS and W.M.L. from the ALF
study group). The IRB of CHS approved all studies. All
liver biopsies and other liver samples studied had been
obtained as part of the standard of care and not as part of
the DILIN study, or of this follow-on study.
Diagnosis of acute DILI was one of exclusion (non-VH,
non-AIH) and based on patient medication history; the
process used by DILIN for assignment of causality was
described previously [12]. Immunoallergic DILI (IAD) was
defined as acute liver injury accompanied by symptoms of
hypersensitivity such as rash, fever, lymphadenopathy,
oedema and eosinophilia. Autoimmune DILI (AID) was
defined as liver injury due to drugs known to cause
such liver injury and accompanied by development of
autoantibodies, a hepatocellular pattern of serum enzyme
elevations [13,14]. Twelve IAD and nine AID cases enrolled
into the prospective protocol of the US Drug Induced Liver
Injury Network (DILIN) [15,16] and consented to partici-
pate in protocols approved by one of the eight clinical sites
of the network were included in the study (Table 1).
Unstained recuts from liver biopsies were made available for
central pathological review [Laboratory of Pathology, NIH
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(DEK)]. The ALF study group biorepository provided tissue
blocks from an additional 11 DILI subjects, including: one
IAD, two AID, six intrinsic and two herbal DILI cases. From
a total of 32 selected DILI cases (DILIN and ALF), seven
were attributed to amoxicillin/clavulanic acid, two to
lamotrigine, six to nitrofurantoin, four to minocycline, six
to acetaminophen and seven to other drugs (Table 1 and
Supporting information, Table S1).
Immunohistochemical (IHC) staining and
histopathological scores
Unstained slides or paraffin-embedded liver blocks were
sectioned and stained at the research histology laboratory at
Carolinas Medical Center (CMC), where the specialized
dual-staining technique for leucocytes was developed, and
applied to the biopsies. After deparaffinization and
rehydration, heat-induced epitope retrieval was performed
using ethylenediamine tetraacetic acid (EDTA) citrate
buffer pH 7·5–8·0 (Polyscientific, Bay Shore, NY, USA). To
demonstrate positive staining of each single-stain antibody,
a tonsil slide and an HBV-positive explanted liver slide were
stained with each antibody individually. Antibodies were
incubated for 1 h at room temperature with the exception
of that for CD4, which was incubated overnight at 4°C.
ImmPRESS peroxidase polymer detection systems for
either rabbit or mouse were used to detect bound anti-
body following the manufacturer’s instructions (Vector
Laboratories, Burlingame, CA, USA). Visualization of
antibody–polymer complex was performed using either
the diaminobenzidine (DAB) or Vector VIP® peroxidase
substrate. Slides were counterstained with methyl green,
dehydrated and mounted with a coverslip and Permount.
Dual staining was carried out according to the Multiple
Antigen Labeling guide published by Vector Laboratories
using the recommended ImmPRESS peroxidase detection
systems described above.
Sections (4 μm) were immunostained for CD11b/CD4
(myeloid Kupffer and T helper cells), CD3/CD20 (T and B
cells) or CD8/CD56 (T cytotoxic and NK cells) (Supporting
information, Table S2). Whenever possible, five portal triads
were scored for each liver biopsy or explanted tissue.
Numbers of cells in portal tracts that stained positively for
CD11b, CD4, CD8, CD3, CD20 or CD56, normalized to
10 000 μm2 surface area, were recorded by two observers
(D.F. and K.C.) and validated independently by two addi-
tional observers (D.E.K., T.W.). Among the 49 subjects with
immunoallergic/autoimmune DILI, AIH and VH enrolled
into the study, 14 needle biopsies had only three to four
observable portal triads.
Hepatic histopathological features were recorded for
all liver biopsies or explanted livers. Fibrosis stage,
necroinflammatory grade, extent of hepatic iron and
fat deposit were scored as described previously [17,18].
Portal plasma cells and neutrophils were evaluated on
haematoxylin and eosin (H&E)-stained liver sections and
scored by D.E.K. or C.J. as 0 (rare or nil) or 1 [prominent
(focal aggregates, numerous)] as described previously
[18].
Statistical methods
Descriptive statistics, including means and standard
deviations (SDs) or counts and percentages, were calcu-
lated for the overall data and by diagnostic category
(immunoallergic DILI, autoimmune DILI, idiopathic AIH
and VH). As multiple measurements were taken on each
subject, repeated-measures analyses using generalized esti-
mating equations (GEE) were performed to compare cell
counts of leucocytes among the five disease groups. For
each liver chemistry and each systemic immune marker,
data were divided into three categories; <lower limit of
normal (LLN), normal and >upper limit of normal
(ULN), and GEE were used to compare cell counts among
the groups. SAS® Enterprise Guide® version 5·1 was used
for all analyses. A two-tailed P-value of less than 0·05 was
considered statistically significant.
Results
Clinical data and pathological assessments
Demographics were similar across disease groups. Sixty-five
per cent of subjects were women and 60% were Caucasians.
By chance, six of 11 subjects with idiopathic AIH were chil-
dren and had lower body mass indices (BMIs). As expected,
high levels of serum alkaline phosphatase, γ-glutamyl
transpeptidase (GGTP) and alanine/aspartate amino-
transferase (ALT and AST) were present (Table 1). Of note,
the non-DILI cohorts had ALT/AST values on average
2·4/1·8 times greater than the immunoallergic (IAD) or
autoimmune (AID) DILI subjects. In addition, the model of
end-stage liver disease (MELD) mean score of intrinsic
DILI cases (ascribed to acetaminophen toxicity) was twice
as high as that of other DILI subjects (Supporting informa-
tion, Table S1). High serum globulins and in particular
immunoglobulin (Ig)G concentrations were observed in
both autoimmune DILI (AID) and idiopathic AIH groups.
While blood haemoglobin, white blood cell and platelet
counts were within the normal range for all four cohorts,
half the DILI subjects had elevated circulating eosinophil
counts, compared with <10% for non-DILI subjects
(Table 1). Histologically, necroinflammatory grades were
elevated in all subjects, but the Ishak fibrosis stage was low
to intermediate (≤3), and only limited fat (≤2) and iron
(≤1) deposits were observed (Table 2).
H&E staining highlighted specific patterns of tissue
damage and local immunological features among the differ-
ent disease groups (Table 2, Supporting information,
Figs S2 and S3). Livers from subjects with idiopathic AIH
D. M. Foureau et al.
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(not due to DILI) had scattered apoptotic hepatocytes with
portal and lobular hepatitis with mixed inflammation,
including lymphocytes, eosinophils, neutrophils and appre-
ciable plasma cell infiltrates. Those from subjects with
immunoallergic DILI (IAD) were characterized by scattered
apoptotic hepatocytes with diffuse portal infiltrates with
prominent eosinophils. Those from subjects with drug-
induced liver injury with autoimmune features (AID) had
extensive necrosis with portal inflammation with a mix of
lymphocytes, macrophages and eosinophils. Of note, 70%
of tissue sections from subjects with AID also displayed
focal aggregates of plasma cells. Livers from subjects with
acute VH had frequent apoptotic hepatocytes, panacinar
hepatitis with mixed inflammatory infiltrates, including
lymphocytes, eosinophils, plasma cells and neutrophils.
Characterization of liver infiltrating leucocytes
Despite heterogeneous immunological features among
disease groups, all the livers studied had portal inflamma-
tion with mixed immune infiltrates of myeloid and
lymphoid origin.
Because Kupffer cells represent the main resident myeloid
cell subset in normal liver [19], we performed CD11b and
CD68 single IHC stains on control tonsil and VH liver
tissue (Supporting information, Fig. S2). Whether tissues
were stained with CD11b or CD68, similar results were
obtained when we performed absolute cell counts of portal
infiltrating myeloid cells (data not shown). Because we
observed less background/non-specific staining with
CD11b, we used it in preference to CD68. Similarly, CD3
and CD20 single IHC stains were performed on control
tonsil and VH liver tissues to identify T and B lymphocytes,
respectively. T lymphocytes were subdivided further into
CD4+ and CD8+ cell subsets. These four markers for IHC
staining of liver-infiltrating lymphocytes showed low back-
ground staining and a high degree of specificity (Fig. 1).
Finally, we performed CD56 and CD57 single IHC stains on
control tonsil and VH liver tissues to label a fifth lymphoid
cell type, i.e. NK cells (Supporting information, Fig. S2).
While tonsil control tissue had only CD57-positive cells,
viral hepatitis control liver tissue showed scattered CD56-
and CD57-positive cells. Parenchymal CD57+ cells consisted
of a mix of small lymphoid (consistent with NK cells) and
larger irregularly shaped bodies (consistent with dendritic
cells). Parenchymal CD56+ cells consisted mainly of bile
ductules, which were distinguishable from infiltrating
CD56+ lymphoid NK cells. Therefore, CD56 was used for
subsequent dual-IHC stains that enumerated portal NK cell
infiltrates during acute hepatitis.
For each subject, three dual-IHC stains were performed
separately: CD11b/CD4 stained for macrophages and CD4+
T cells, CD20/CD3 stained for B/T lymphocytes and CD56/
CD8+ stained for NK/CD8 T cells (Fig. 1). Overall CD11b+
macrophages and CD3+ T cells were found throughout theTa
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liver and represented the main components of myeloid
and lymphoid portal hepatic infiltrating leucocytes.
Subcategorization of T cells showed that CD4+ T lympho-
cytes were rare and that portal hepatic T cells were mainly
CD8+. Mature (CD20+) B cells and CD56+ NK cells were
relatively rare and distributed unevenly across the livers.
Parenchymal B cells were widely scattered single cells and
small clusters, while portal B cells tended to form small
aggregates when present at all.
Associations among leucocyte infiltrates and causes of
acute hepatitis
To correlate qualitative and quantitative assessments of
portal hepatic infiltrating leucocytes with underlying causes
of acute hepatitis, stained cells were counted within up to
five portal areas per slide, normalized to 10 000 μm2 areas,
and averaged. Infiltrates of macrophages (CD11b+) were
highly heterogeneous among patients with acute hepatitis,
but no pattern emerged that was associated with any par-
ticular underlying liver condition (Fig. 1, Table 2 and Sup-
porting information, Table S1). Portal T lymphocytes
(CD3+) were highly represented among all disease groups
and were mainly cytotoxic T cells (CD8+). CD4 T lympho-
cytes were a comparatively rare cell subset (<10% of total
T cells) (Fig. 2, Table 2 and Supporting information,
Table S1). Of note, T cell portal infiltrates were correlated
inversely with age and BMI: paediatric subjects (aged 1–18
years) and/or subjects with a BMI <20 kg/m2 had fewer
numbers of CD3+ infiltrating cells (data not shown). While
the idiopathic AIH cohort had a demographic bias towards
the paediatric population with lower BMI, the degree of
portal CD3+ infiltrating T cells was similar across all disease
groups.
B cells (CD20+) were found rarely in biopsies of
DILI subjects, with averages of only 1·2 ± 1·3 (IAD),
2·2 ± 1·9 (AID) and 0·6 ± 1·4 (intrinsic DILI) cells per
10 000 μm2 portal areas, respectively (Fig. 3, Table 2 and
Supporting information, Table S1). Conversely, the biopsies
of non-DILI subjects were characterized by significantly
greater B cell infiltrates regardless of the cause of acute
hepatitis (P < 0·0001 compared with DILI cohorts). The
number of NK cells (CD56+) allowed further discrimina-
tion among non-DILI subjects: subjects with idiopathic
AIH had rare CD56+ infiltrating cells (0·3 ± 0·6), while
patients with VH had significantly higher frequencies of
such cells (3·1 ± 3·3 per 10 000 μm2, P < 0·0001) (Fig. 3,
Table 2).
Tonsil
CD4
CD11b
CD3
CD20
CD8
CD56
Liver
Dual stain CD4/CD11b
Dual stain CD3/CD20
Dual stain CD8/CD56
Fig. 1. Haematoxylin and eosin (H&E)
histochemical, single and
dual-immunohistochemistry stains of control
lymphoid tissue (tonsil) and hepatits B virus
(HBV)+ liver tissue. Staining for Kupffer
cells (CD11b), B cells (CD20) and natural
killer (NK) cells (CD56) used visual
immunoprecipitate assay (VIP) (purple)
colorimetric substrate, whereas staining for T
cells (CD3) and T cell subsets (CD4–CD8) used
diaminobenzidene (DAB) (brown) colorimetric
substrate.
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Comparative analyses of liver infiltrates with liver
damage/function
Macrophages and T lymphocytes represented the two main
types of leucocytes in portal tracts during acute hepatitis.
While the degree of infiltration did not correlate with spe-
cific underlying causes of acute hepatitis, both cell types
tended to be more prevalent in liver specimens that showed
enlarged portal triads and/or greater tissue damage (data
not shown). To explore a potential link between overall liver
damage and leucocyte infiltrates, CD11b+ and CD3+ scores
were compared with results of selected liver test measure-
ments (Table 3). Degrees of macrophage portal infiltrates
were much higher in patients with altered hepatic function.
For instance, subjects with elevated serum total bilirubin
had, on average, four times more CD11b+ cells than did
their counterparts with normal serum bilirubin levels. A
similar pattern was observed for subjects with ALT and AST
values >ULN (respectively, 3·7- and 2·3-fold greater CD11b
infiltration, compared with those with levels within normal
range). T cell (CD3+) analysis showed that patients with
elevated ALT or AST levels had approximately 30% fewer
portal hepatic CD3+ cells than did those with levels of these
analytes that were within the normal range.
Comparative analyses of liver infiltrates with peripheral
markers of immunity
We did not find associations between any particular portal
immune cell infiltrate and non-specific markers of systemic
immunity, such as absolute eosinophil or white blood cell
counts. To estimate the extent to which liver infiltrating leu-
cocytes are representative of systemic immune events, we
performed analyses that compared intrahepatic cell counts
with serum markers of immune activation (presence of cir-
culating autoantibodies and circulating immunoglobulin
levels) (Table 4). Markers of autoimmunity such as presence
and titres of circulating anti-nuclear (ANA), anti-smooth
muscle actin (ASMA) or anti-mitochondrial (AMA)
autoantibodies were associated directly with greater than
normal levels of infiltrating CD20+ B cells (P < 0·0001)
(Table 4). Eosinophilia, used commonly as a marker of
allergic reactions, was associated with an overall lesser
degree of liver inflammation. Patients with greater than
normal circulating eosinophil counts had fewer liver infil-
trating CD11b+ macrophages (P = 0·006), CD4+ T cells
(P < 0·0001) and CD20+ B cells (P < 0·0001). In contrast, in
subjects with hypergammaglobulinaemia (another periph-
eral marker for autoimmunity), the opposite trend was
observed for macrophages (CD11b+ cells) accumulated
within portal areas (P < 0·0001) (Table 4).
Discussion
In this work we evaluated systematically the profiles of infil-
trating leucocytes in DILI cases compared to other causes of
acute liver injury. The major novel findings of this work are
as follows: (i) we have developed and optimized methods
for performing dual-IHC staining and for enumerating
mononuclear inflammatory cells in liver biopsies of subjects
with acute liver injury of diverse causes, including immune-
mediated or ‘intrinsic’ (acetaminophen-induced) DILI, idi-
opathic AIH and viral hepatitis (Figs 1–4). (ii) In liver
biopsies of subjects with clinically important acute DILI
caused by any of five drugs commonly incriminated
as causes of immunoallergic DILI (amoxicillin/clavulanic
acid or lamotrigine), autoimmune DILI (minocycline or
nitrofurantoin) or intrinsic DILI (acetaminophen), the pre-
dominant leucocytes present are T cells (CD3+), not B cells
(CD20+) or NK cells (CD56+) (Figs 3 and 4 and Supporting
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Fig. 2. Portal-infiltrating Kupffer cells
(CD11b+) were found in all livers studied. Cell
counts were normalized to the size of portal
triads and averaged for each subject. Results are
means ± standard deviation.
AID = autoimmune drug-induced liver injury
(DILI); AIH = idiopathic autoimmune hepatitis;
IAD = immune-allergic DILI; VH = viral
hepatitis.
Liver leucocytes in acute hepatitis
7© 2014 British Society for Immunology, Clinical and Experimental Immunology
D. M. Foureau et al.
46 VC 2014 British Society for Immunology, Clinical and Experimental Immunology, 180: 40–51
information, Table S1). In all biopsies studied, regardless of
underlying cause, the great majority (> 90%) of T cells are
cytotoxic (CD8+), rather than T helper (CD4+) cells (Table 2
and Supporting information, Table S1, Fig. 3). (iii) B cells
(CD20+) are few in number in acute DILI, regardless of
cause or presence of positive markers of autoimmunity in
serum (positive AMA, ANA or ASMA), whereas such B cells
are commonly present in idiopathic AIH or VH (Table 2,
Fig. 4). (iv) Natural killer (CD56+) cells were undetectable
or rare in all forms of injury, except for VH (Table 2,
Fig. 4b).
Our results extend knowledge of the numbers and types
of mononuclear immune cells that occur in liver biopsies of
subjects with acute DILI. Heretofore, such staining and
characterization had been limited to individual case reports
[20]. Our finding of a consistent predominance of cytotoxic
(CD8+) T cells in the biopsies of DILI subjects is supportive
of the hypothesis that, for several drugs well known as
causes of DILI, the pathogenesis of liver injury involves
drug-induced critical alterations of hepatocytes and/or
cholangiocytes which, in turn, activate the susceptible hosts’
immune systems to infiltrate their livers and to attack and
damage or destroy hepatocytes (usually the primary foci of
injury) and/or cholangiocytes (less frequently the primary
foci of injury). The frequent occurrence of apoptotic
bodies, of hepatocyte swelling and other typical changes of
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Fig. 3. CD8+ T cells were the main
mononuclear cell type infiltrating the portal
triads of injured livers. Total T cells (a) or
CD4/CD8 subsets (b) counts were performed
using a pan-T cell marker (CD3) or T helper
(CD4)/T cytotoxic markers (CD8), normalized
to the portal triads size, and averaged for each
subjects. Results are means ± standard
deviation.
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hepatocyte injury (Supporting information, Fig. S1) [21]
provides additional evidence for this pathogenic sequence.
Still unknown for most cases of acute DILI are the precise
molecular mechanisms whereby commonly used drugs,
such as amoxicillin/clavulanic acid or nitrofurantoin, elicit
injury in only a small percentage of people who take these
drugs. However, generation of neoantigens produced by the
drugs or their metabolites interacting with host proteins
(e.g. albumin or other plasma/intracellular proteins) [22]
may be the initiating event and, because antigens are dis-
played on the plasma membranes of hepatocytes and/or
cholangiocytes, call forth activation and expansion of T
cells, especially of the CD8+ cytotoxic T cells, which pre-
dominate in the liver biopsies (Table 2, Figs 3 and 4). More
likely than not, the innate immune status of the host (HLA
type) is also important.
Similar mechanisms have been posited for autoimmune
DILI, idiopathic AIH and VH [23], and the similarities in T
Table 3. Associations between leucocyte cell counts in livers and liver chemistries.
Normal >ULN
P-valuen Mean (± s.d.) n Mean (± s.d.)
D. Bili CD11b 7 1·9 (± 1·0) 26 6·48 (± 5·4) <0·0001
CD3 14·4 (± 8·0) 12·7 (± 8·4) 0·0003
T. Bili CD11b 12 1·5 (± 1·1) 37 6·0 (± 5·2) 0·0002
CD3 14·6 (± 8·7) 13·1 (± 8·5) 0·1885
Alk. Phos CD11b 13 3·1 (± 3·5) 35 5·8 (± 5·4) 0·1549
CD3 13·6 (± 8·6) 13·7 (± 8·6) 0·1183
GGTP CD11b 12 5·1 (± 4·5) 17 5·9 (± 5·8) 0·4193
CD3 13·1 (± 9·6) 12·3 (± 7·4) 0·5054
ALT CD11b 5 1·4 (± 1·0) 44 5·3 (± 5·1) 0·0015
CD3 19·1 (± 7·8) 13·0 (± 8·5) 0·0002
AST CD11b 7 2·3 (± 2·2) 42 5·3 (± 5·2) 0·0823
CD3 18·5 (± 7·7) 12·8 (± 8·5) 0·0012
Bolded characters highlight P-values <0.05. Alk. Phos = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase;
GGTP = γ-glutamyl transpeptidase; D. Bili = direct bilirubin; T. Bili = total bilirubin; s.d. = standard deviation; ULN = upper limit of normal.
Table 4. Associations among cell counts and systemic immune markers.
<LLN Normal >ULN
P-valuen Mean (± s.d.) n Mean (± s.d.) n Mean (± s.d.)
Absolute eosinophil CD11b 32 5·9 (± 5·3) 16 1·9 (± 2·3) 0·0006
CD4 1·0 (± 1·0) 0·1(± 0·2) <0·0001
CD20 4·3 (± 5·3) 1·2 (± 1·3) <0·0001
WBC CD11b 8 3·3 (± 3·7) 31 5·4 (± 5·3) 10 5·2 (± 7·9) 0·6727
CD4 0·9 (± 1·0) 0·8 (± 0·7) 0·7 (± 1·4) 0·6585
CD20 4·3 (± 4·6) 2·8 (± 3·0) 4·9 (± 8·2) 0·7871
ANA* CD11b 21 5·5 (± 4·6) 22 4·9 (± 5·6) 0·5639
CD4 0·7 (± 0·7) 0·9 (± 1·1) 0·1787
CD20 2·7 (± 3·3) 4·4 (± 5·9) 0·0293
ASMA* CD11b 20 3·2 (± 3·6) 22 7·0 (± 5·8) 0·0208
CD4 0·5 (± 0·6) 1·1 (± 1·1) 0·2451
CD20 1·7 (± 1·8) 5·0 (± 6·0) <0·0001
AMA* CD11b 20 4·3 (± 5·9) 12 6·7 (± 4·9) 0·5195
CD4 0·6 (± 0·7) 0·9 (± 0·8) 0·7812
CD20 1·8 (± 1·8) 7·7 (± 3·9) <0·0001
Total globulin CD11b 10 1·9 (± 1·8) 31 5·4 (± 5·3) 0·1609
CD4 0·9 (± 1·2) 0·8 (± 0·9) 0·3145
CD20 4·8 (± 5·2) 3·5 (± 5·0) 0·4439
IgG CD11b 5 0·5 (± 0·5) 14 5·3 (± 4·7) <0·0001
CD4 0·7 (± 0·7) 1·2 (± 1·2) 0·1640
CD20 0·0 (± 0·0) 5·7 (± 7·1) 0·0639
*Negative or positive results instead of normal or > upper limit of normal (ULN), respectively. Bolded characters highlight P-values <0.05.
AMA = anti-mitochondrial autoantibodies; ANA = anti-nuclear autoantibodies; ASMA = anti-smooth muscle autoantibodies; Ig = immunoglobulin;
LLN = lower limit of normal; WBC = white blood cells.
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cell counts and distributions across several aetiologies of
acute hepatitis in our studies support this view (Table 2,
Fig. 3). However, there are also some important differences
in leucocyte patterns comparing, for instance, DILI and
non-DILI causes; namely, the higher numbers of mature B
(CD20+) cells in non-DILI acute hepatitis (Fig. 4a). Hepatic
infiltrating plasma cells (e.g. fully differentiated B cells),
used commonly to establish the diagnosis of idiopathic AIH
[24,25], lack CD20 expression. While plasma cell infiltrates
indeed characterized idiopathic AIH subjects in our study,
the majority of autoimmune cases caused by drugs also
shared the same feature (Supporting information, Fig. S3).
Combined analysis of portal CD20+ mature B cells and
plasma cells therefore provided a better discrimination
between idiopathic AIH and AID patient cohorts. Similarly,
among subjects with notable hepatic B cell infiltrates, fre-
quent CD56+ NK cells in biopsies allowed further discrimi-
nation among the idiopathic AIH and VH patient
populations (Fig. 4b).
Our results will, of course, benefit from confirmation in
larger numbers of subjects with acute DILI and with other
aetiologies of hepatitis. Such studies are planned in the
future, and we hope that other groups will study additional
unique cohorts of subjects to ascertain whether our findings
can be confirmed. We are not suggesting that similar find-
ings will be observed in all instances of DILI. For example,
DILI due to acetaminophen leads typically to variably
severe zone 3-centred hepatocyte necrosis. Early in the
B cells (CD20+)25
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Fig. 4. Portal infiltrating B cells (CD20+) were
found primarily in non-drug-induced liver
injury (DILI)-related injury; presence of natural
killer (NK) cells (CD56+) allowed further
discrimination between viral hepatitis (VH)
versus idiopathic autoimmune hepatitis (AIH)
patients. (a) B cells (CD20+) and (b) NK cells
(lymphoid CD56+) normalized to the size of
portal triads and averaged for each subject.
Results are means ± standard deviation.
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course of such injury, there is little hepatic infiltration with
mononuclear inflammatory cells, owing probably to the fact
that the injury and necrosis of hepatocytes are due to the
intrinsic toxic effects of N-acetyl-p-benzoquinone imine
(NAPQI). Inflammatory infiltrates, mainly neutrophils and
macrophages, develop later. Recent studies suggest that they
mediate injury as well as serve a ‘clean up’ function in aceta-
minophen toxicity [26,27]. This is in stark contrast to DILI
caused by 17-alkylated anabolic steroids, which is character-
ized typically by prolonged and variably severe cholestasis.
Liver biopsies of subjects with such DILI typically show
‘bland’ cholestasis with bile in hepatocytes, bile plugs in
canaliculi and ductules, but with minimal inflammation. In
liver injury caused by anabolic steroids, a primary alteration
of bile salt and/or other transporters appears to be the key
factor in pathogenesis [28,29]. Perhaps those susceptible to
DILI due to such 17-alkylated anabolic steroids have genetic
or acquired defects in these transporters, which predispose
them to injury.
Among the strengths of the current work are that we have
screened several primary and secondary antibodies,
optimized staining conditions and protocols and estab-
lished dual-IHC staining, which requires only three 4-μm-
thick sections of each biopsy. We also studied 32 well-
characterized subjects from the US DILIN or ALF study
group adjudged definitely (>95% likelihood) or very likely
(75–94% likelihood) to have had acute DILI due to the
incriminated drugs. The US DILIN has developed and vali-
dated structured methods for case summarization and
assessment of causality [30]. All other potential causes were
searched for and excluded, including acute viral hepatitis
A–E.
Our study also has limitations: thus far, we have studied
only subjects with acute hepatitis. It would be of benefit to
study larger numbers of subjects of both DILI and non-
DILI causes and to study biopsies from subjects with DILI
due to several other drugs in order to assess the extent to
which our initial results extend to other drugs. In addition,
extending our hepatic immune phenotyping methodology,
using dual-IHC to cases of chronic hepatitis such as alco-
holic or non-alcoholic steatohepatitis (ASH, NASH) could
provide additional information regarding the ubiquity of
interplay among the most prominent adaptive immune
variables observed in our study (CD8+ T cells and CD20+ B
cells).
Conclusions
In summary, we have developed and optimized procedures
for dual-staining IHC of mononuclear immune cells in liver
biopsies and have characterized the mononuclear cells that
infiltrate the portal tracts of biopsies from subjects with
immunoallergic, autoimmune and intrinsic DILI. Regard-
less of the causative drug or the clinicopathological pheno-
type, the predominant cell types are T cells (CD3+), not B
cells (CD20+) or NK cells (CD 11+ or CD 56+), and nearly all
the T cells are cytotoxic (CD8+), rather than T helper cells
(CD4+). In contrast, B cells are numerous in idiopathic AIH,
VH and NK cells are found in VH. Our findings provide
insight into potential pathogenic mechanisms of hepatitis
and, we speculate, will prove useful in establishing the
correct aetiological agent responsible for acute hepatitis,
especially in the still-problematic assessment of whether
due to drug- or non-drug causes. Although not powered to
establish thresholds of clinically relevant B, NK and plasma
cell infiltrates, this study allowed us to develop a concept
algorithm to help establish a correct diagnosis among IAD,
AID, idiopathic AIH and VH (Supporting information,
Fig. S4). While prominent mature B cells (CD20+) differen-
tiate DILI from non-DILI cases, NK cells (CD56+) further
differentiate AIH and VH subjects, and plasma cell counts
help to distinguish autoimmune from immunoallergic
DILI.
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Figure S1. Haematoxylin and eosin (H&E) histochemical
stains highlighting immunological features of drug-induced
liver injury (DILI), autoimmune hepatitis, hepatitis B virus
(HBV) and cryptogenic hepatitis.
Figure S2. Representative single immunohistochemical
staining output for macrophages (CD11b versus CD68) and
natural killer (NK) cells (CD56 versus CD57) on control
lymphoid tissue (tonsil) and hepatitis B virus (HBV)+ liver
tissue.
Figure S3. Percentile of acute hepatic cases with prominent
portal hepatic infiltrating plasma cells and neutrophils.
Figure S4. Concept algorithm to help establishing differen-
tial diagnosis among immune-allergic drug-induced liver
injury (DILI) (IAD), autoimmune DILI (AID), idiopathic
autoimmune hepatitis (AIH) and viral hepatitis (VH)
patients using portal hepatic-infiltrating monocular cell
analysis.
Table S1. Demographic, laboratory results and
histopathological findings in subjects with drug-induced
liver injury (DILI) due to acetaminophen (‘intrinsic’) or
herbal products.
Table S2. Primary antibodies used.
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